Oversight of Medicine Handling at Pharmacy Service Facilities: PERATURAN BPOM 5/2026

Indonesia's food and drug authority has issued rules governing how it supervises the handling of medicines and drug materials at the point where they reach patients. Peraturan Badan Pengawas Obat dan Makanan Nomor 5 Tahun 2026 tentang Pengawasan Pengelolaan Obat dan Bahan Obat di Fasilitas Pelayanan Kefarmasian dan Fasilitas Lain (Regulation of the Food and Drug Supervisory Agency No. 5 of 2026 on the Supervision of the Management of Medicines and Drug Materials at Pharmaceutical Service Facilities and Other Facilities) contains 28 articles and reaches pharmacies, clinics, hospitals and the other categories of facility that store and dispense medicines.

Issue

Supervision of pharmaceutical products in Indonesia has long been strongest at the manufacturing and distribution stages, where licensing and good-practice certification apply. The final segment of the chain — the dispensing outlet — sits closer to the patient and holds smaller quantities, but it is also where controlled substances are most exposed to diversion. The regulation gives the agency a written basis for entering these premises, examining records and referring suspected offences onward.

Pasal 1 fixes the vocabulary the rest of the text depends on. It defines Obat (medicine) as a substance or combination of substances, including biological products, used to affect or investigate physiological systems or pathological states for diagnosis, prevention, cure, recovery, health improvement and contraception in humans. Bahan Obat (drug material) covers active and inactive substances used in preparing medicines to pharmaceutical standards. The same article separately defines narcotics, psychotropics and pharmaceutical precursors — the last listed by named chemicals including ephedrine, pseudoephedrine, norephedrine, ergotamine, ergometrine and potassium permanganate. It also defines Apoteker (pharmacist), Petugas (the civil-service officer assigned to supervision duties) and Kepala Badan (the Head of the Agency).

Key Provisions

Two layers of supervision operate in parallel. Under Pasal 11, management of medicines and drug materials at the facilities identified in Pasal 5 must be supervised internally by the facility's designated responsible person. Under Pasal 12(1), supervision of that same management is separately carried out by the Head of the Agency.

Pasal 12(2) divides agency supervision into routine and incidental forms. Routine supervision runs through examination of the reports that facilities already submit under existing rules, and through scheduled field inspection. Incidental supervision is conducted at times the agency selects. Both field forms are executed by officers, whose powers are enumerated in Pasal 12(6): examining any document, location, facility or premises; examining licences; taking data, information and documents, including images, photographs and video; conducting verification, clarification and assessment; taking on-site securing measures; issuing recommendations based on supervision findings; and carrying out other statutory duties.

Pasal 13 attaches a procedural condition to those powers. An officer conducting an inspection must carry a written assignment order and an identity card. Where the officer does not hold both, the person responsible for the premises may refuse the inspection. The right of refusal is stated in the regulation itself rather than left to general administrative practice.

Pasal 17 sets the handover point to law enforcement. Where supervision findings indicate a suspected criminal offence in the field of medicines and drug materials — including offences involving narcotics, psychotropics or pharmaceutical precursors — the officer must promptly coordinate with investigators under the applicable legislation. Chapter IV, which follows immediately, sets out the prohibitions that apply at these facilities.

Pasal 10 carves out one category. Medicine management at village or sub-district pharmacies and clinics operating under a koperasi desa merah putih (red-and-white village cooperative) follows technical guidelines issued by the minister responsible for health affairs, connecting this instrument to the health ministry's own facility rules rather than resolving those arrangements internally.

Implications

Facilities holding medicines will need a named responsible person able to demonstrate that internal supervision under Pasal 11 is functioning, since that obligation is now written rather than implied by professional standards. Because routine supervision draws on periodic reports before any inspector arrives, reporting accuracy carries direct weight in whether a facility attracts a field visit.

The enumerated officer powers in Pasal 12(6) include photographic and video collection and on-site securing measures, so inspection records may be created and retained beyond the paper file. The Pasal 13 warrant requirement gives facility staff a specific document to check at the door. Outlets handling narcotics, psychotropics or precursor chemicals fall within the Pasal 17 referral route, which places their storage and dispensing records at the front of any supervision encounter.

Regulatory Context

The regulation sits alongside the agency's other 2026 rulemaking, including its parallel instrument issued the same year, and alongside the health ministry's facility and service standards such as the 2026 ministerial rules on health service arrangements. Its subject matter connects the pharmaceutical supervision regime to the narcotics, psychotropics and precursor control statutes referenced throughout the definitions in Pasal 1.

Read the full regulation in the CRPG Law Database.

Methodology: This memo summarises the official regulation text and is not legal advice; report corrections to contact@crpg.info.

Disclaimer

This article was AI-generated under an experimental legal-AI application. It may contain errors, inaccuracies, or hallucinations. The content is provided for informational purposes only and should not be relied upon as legal advice or authoritative interpretation of regulations.

We accept no liability whatsoever for any decisions made based on this article. Readers are strongly advised to:

• Consult the official regulation text from government sources
• Seek professional legal counsel for specific matters
• Verify all information independently

This experimental AI application is designed to improve access to regulatory information, but accuracy cannot be guaranteed.